Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Analgesic / Antipyretic Pregnancy: §4.6, verbatim: 'Pregnancy — A large amount of data on pregnant women indicate neither malformative, nor feto/neonatal toxicity. Epidemiological studies on neurodevelopmental disorders in children exposed to paracetamol in utero show inconclusive results. If clinically needed, paracetamol can be used during pregnancy for the shortest possible time, at the lowest effective dose and at the lowest possible frequency. Breastfeeding — Paracetamol is excreted into breast milk. No undesirable effects on nursing infants have been reported. Paracetamol 500 mg capsules, soft may be used in therapeutic dosages in breast-feeding women.'

Paracetamol (Elderly)

Brand names: Panadol, Calpol

Paracetamol (in older people) is a simple analgesic and antipyretic and is the recommended first-line option for mild-to-moderate pain in this group.

Adult dose

Dose: 500-1000 mg (one to two 500 mg soft capsules) per dose, by mouth — the standard adult regimen, which this label applies to adults of any age because it states no elderly-specific dose. §4.2 Posology, verbatim: 'For adults and children aged 16 years and older, the usual dosage is 1 to 2 capsules (500-1000 mg) at a time, up to four times daily as required, with a maximum of 8 capsules (4000 mg) every 24 hours.' NO AGE-BASED REDUCTION IS STATED anywhere in the fetched label; the reduced ceilings a frail older patient may need are covered by the §4.4 cautions quoted in the notes and hepatic fields, not by an elderly posology. ORAL 500 mg CAPSULES ONLY: no intravenous or rectal label is in this bundle, so no dose is published for the page's 'IV, rectal' routes.
Route: Oral — Panadol 500 mg soft capsules. §4.2 Method of administration, verbatim: 'Capsule — The capsules should be swallowed with enough water. The intake of paracetamol with food or drink doesn't influence the efficacy of the medicine.' SCOPE: no IV or rectal paracetamol label is in this bundle, so the page's IV and rectal routes are unsourced and no dose is published for them.
Frequency: Up to four times daily as required. §4.2, verbatim: 'These doses should not be repeated more frequently than every four hours nor should more than four doses be given in any 24 hour period.' and 'The administration interval must be at least 4 hours.'
Max: Maximum 8 capsules (4000 mg) every 24 hours — adults and children aged 16 years and older (§4.2, verbatim: 'with a maximum of 8 capsules (4000 mg) every 24 hours').
ELDERLY — WHAT THE SOURCE ACTUALLY SAYS: nothing specific. There is no 'Elderly' heading in §4.2 and no age-based reduction anywhere in the fetched sections, so the adult regimen above applies unchanged. The ONLY reduced ceiling this label states is §4.4, verbatim: 'The risk of an overdose is greater in patients with non-cirrhotic alcoholic liver conditions. Caution is required in the case of chronic alcoholism. The daily dose may not exceed 2 grams in this case.' || §4.4 cautions that commonly apply to frail older patients, verbatim: 'Caution is required when administering paracetamol to patients with moderate to severe renal insufficiency, mild to moderate hepatic insufficiency (incl. Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh > 9), acute hepatitis, the concomitant administration of medicinal products which have an influence on hepatic function, glucose-6-phosphate dehydrogenase deficiency, haemolytic anaemia, alcohol abuse, dehydration and chronic malnutrition.' || CUMULATIVE EXPOSURE, §4.2/§4.4 verbatim: 'Do not use in combination with other paracetamol-containing products' and 'Patients must be advised not to use any other paracetamol-containing products at the same time' — the fetched label does not name combination products, so the page's co-codamol/cold-remedy examples are practice advice, not source text. || §4.2 instructions for use, verbatim: 'The treatment should be kept as short as possible. The administration interval must be at least 4 hours. Do not exceed the recommended daily dose on account of the risk of severe hepatic damage... If pain lasts for longer than 5 days or fever lasts for longer than 3 days or these symptoms become worse or if other symptoms occur, the treatment must be stopped, and a doctor must be consulted.'

Dose adjustments

Renal

Not stated as a dose adjustment — this label gives no renal dosing rule. §4.4 records a caution only, verbatim: 'Caution is required when administering paracetamol to patients with moderate to severe renal insufficiency...' Absence of a stated adjustment is not evidence that none is needed; check the full current SPC.

Hepatic

§4.4, verbatim: 'The risk of an overdose is greater in patients with non-cirrhotic alcoholic liver conditions. Caution is required in the case of chronic alcoholism. The daily dose may not exceed 2 grams in this case. No alcohol may be used during treatment with paracetamol.' §4.4 also lists as requiring caution 'mild to moderate hepatic insufficiency (incl. Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh > 9), acute hepatitis, the concomitant administration of medicinal products which have an influence on hepatic function... and chronic malnutrition', but states no reduced dose for those groups. The 2 g/day ceiling above is stated ONLY for the chronic-alcoholism / non-cirrhotic alcoholic liver case.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • §4.3, verbatim and complete — the only contraindication in this label: 'Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1'
  • Not a §4.3 contraindication but a §4.4 absolute instruction: 'The recommended dose should not be exceeded.' and 'Patients must be advised not to use any other paracetamol-containing products at the same time.'
  • Not a §4.3 contraindication but a §4.4 bar in chronic alcoholism: 'The risk of an overdose is greater in patients with non-cirrhotic alcoholic liver conditions. Caution is required in the case of chronic alcoholism. The daily dose may not exceed 2 grams in this case. No alcohol may be used during treatment with paracetamol.'
  • §4.4 cautions (not contraindications): 'moderate to severe renal insufficiency, mild to moderate hepatic insufficiency (incl. Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh > 9), acute hepatitis, the concomitant administration of medicinal products which have an influence on hepatic function, glucose-6-phosphate dehydrogenase deficiency, haemolytic anaemia, alcohol abuse, dehydration and chronic malnutrition'; also 'asthmatic patients who are sensitive to acetylsalicylic acid as mild bronchospasms have been reported as a cross-reaction'; and patients 'with glutathione depleted states, as the use of paracetamol may increase the risk of metabolic acidosis'.
  • Excipients, §4.4 verbatim: 'This medicine contains 20 mg propylene glycol in each soft capsule.' and 'This medicine contains 108 mg sorbitol liquid in each soft capsule. Sorbitol is a source of fructose' — relevant in hereditary fructose intolerance.
  • INCOMPLETE LIST WARNING: §4.4 was truncated at the source-fetch limit mid-sentence, so any further bars stated after the sorbitol paragraph were not retrieved.

Side effects

  • §4.8 summary, verbatim: 'At therapeutic doses few undesirable effects occur.'
  • Very rare (<1/10,000), §4.8: thrombocytopenia; agranulocytosis
  • Very rare (<1/10,000), §4.8: 'Anaphylaxis. Cutaneous hypersensitivity reactions including, among others, skin rashes and angiodema. Very rare cases of serious skin reactions have been reported.'
  • Very rare (<1/10,000), §4.8: bronchospasm — 'There have been cases of bronchospasm with paracetamol, but these are more likely in asthmatics sensitive to aspirin or other NSAIDs.'
  • Very rare (<1/10,000), §4.8: hepatic dysfunction
  • Frequency not known, §4.8: 'High anion gap metabolic acidosis — Cases of high anion gap metabolic acidosis due to pyroglutamic acidosis have been observed in patients with risk factors using paracetamol (see section 4.4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients.'
  • §4.4, verbatim: 'The taking of several daily doses at once can cause severe damage to the liver. In such cases, a loss of consciousness will not occur. However, immediate medical help must be sought even if the patient feels well because of the risk of irreversible damage to the liver.'

Monitoring

  • Overdose vigilance — §4.4, verbatim: 'The taking of several daily doses at once can cause severe damage to the liver... immediate medical help must be sought even if the patient feels well because of the risk of irreversible damage to the liver (see section 4.9).'
  • Total paracetamol exposure — §4.4, verbatim: 'Patients must be advised not to use any other paracetamol-containing products at the same time.' (§4.2 repeats: 'Do not use in combination with other paracetamol-containing products.')
  • Duration and response — §4.2, verbatim: 'If pain lasts for longer than 5 days or fever lasts for longer than 3 days or these symptoms become worse or if other symptoms occur, the treatment must be stopped, and a doctor must be consulted.' and 'The treatment should be kept as short as possible.'
  • Long-term use — §4.4, verbatim: 'Long-term or frequent use is not advised' and 'Long-term use can be harmful except under medical supervision.'
  • Analgesic-overuse headache — §4.4, verbatim: 'After the long-term use (> 3 months) of analgesics with intake every other day or more frequently, headache can occur or become worse. Headache which is caused by the excessive use of analgesics (drug-dependent headache) must not be treated by increasing the dose.'
  • Persisting fever — §4.4, verbatim: 'In the case of a high fever, symptoms of secondary infection or the persistence of symptoms, it will be necessary to reconsider the treatment.'
  • No routine laboratory monitoring is required by this label at therapeutic doses, and none is asserted here.
  • This list may be incomplete — check the full SPC.

Clinical monograph

How it works

Its analgesic and antipyretic actions are thought to involve central inhibition of prostaglandin synthesis and modulation of pain pathways, with little peripheral anti-inflammatory effect.

Prescribing in practice

  • In frail, low-body-weight or chronically malnourished older people, and in those with hepatic impairment or chronic high alcohol intake, a reduced total daily dose may be appropriate to limit hepatotoxicity risk.
  • Account for paracetamol contained in combination analgesics and over-the-counter products to avoid inadvertent excess.
  • It is preferred over NSAIDs in older people because it avoids gastrointestinal, renal and cardiovascular NSAID hazards.

Monitoring

Routine monitoring is not required, but review cumulative intake and consider hepatic status in frail or low-weight older patients.

Counselling the patient

  • Do not take other products that also contain paracetamol at the same time.
  • Take regularly rather than only when pain is severe for steadier control.

Evidence & guidelines

NICE guidance positions paracetamol as a first-line analgesic, and it is generally favoured over NSAIDs in older adults because of its safer organ profile.

Reference: AGS guidelines; NICE NG193; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways